Advertisement

Topics

A Cure for Alzheimer’s by 2025? An Interview with Jeff Cummings, M.D.

10:47 EDT 23 Aug 2017 | Drug Discovery Development

A report released by the Cleveland Clinic last month shared some disappointing news. Its second assessment of the Alzheimer drug pipeline revealed a slow period in drug development with only eight new agents entering Phase I since 2016. In order for an agent to be approved by 2025 it must currently be in mid- to late-Phase II to be on track. While there are promising agents in all phases of the pipeline, high drug failure rates, lack of clinical trial participants as well as lack of funding can slow the path to approval. But there's still reason to be optimistic.
Staff Author: 
Topics: 

Original Article: A Cure for Alzheimer’s by 2025? An Interview with Jeff Cummings, M.D.

NEXT ARTICLE

More From BioPortfolio on "A Cure for Alzheimer’s by 2025? An Interview with Jeff Cummings, M.D."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...